Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 03:26:34 2024-05-15 pm EDT			5-day change	1st Jan Change
4.455 ^USD	-3.99%		-5.63%	+32.69%

May. 09	Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000	MT

Applied Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 07:41 am EDT

Applied Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 29.58 million compared to USD 25.86 million a year ago. Basic loss per share from continuing operations was USD 0.37 compared to USD 0.96 a year ago.
For the six months, revenue was USD 10.66 million. Net loss was USD 39.71 million compared to USD 48.98 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 1.84 a year ago.

Latest news about Applied Therapeutics, Inc.

Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000	May. 09	MT
Applied Therapeutics, Inc. Announces Management Changes	Apr. 15	CI
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	Mar. 28	DJ
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment	Mar. 28	DJ
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours	Mar. 28	MT
US FDA extends review of Applied Therapeutics' genetic disease drug	Mar. 28	RE
Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia	Mar. 28	CI
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'	Mar. 26	MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating	Mar. 15	MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating	Mar. 06	MT
Applied Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q4 Revenue $10M	Mar. 06	MT
Applied Therapeutics, Inc. announced that it has received $99.997998 million in funding from a group of investors	Feb. 29	CI
Applied Therapeutics' NDA for Govorestat Accepted by FDA; Launches $100 Million Private Placement; Shares Jump	Feb. 28	MT
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round	Feb. 28	DJ
Leerink Partners Initiates Applied Therapeutics at Outperform Rating $12 Price Target	Feb. 22	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 16	MT
Sector Update: Health Care	Feb. 16	MT
Applied Therapeutics Says Phase 3 Trial of Govorestat Meets Interim Primary Goal; Shares Rise	Feb. 16	MT
Transcript : Applied Therapeutics, Inc. - Special Call	Feb. 15
Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial	Feb. 15	CI
Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase Deficiency	Feb. 15	CI
Wall Street ends topsy-turvy day marginally up	Jan. 05	RE
Top MIdday Decliners	Jan. 05	MT

Chart Applied Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companyâs lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Applied Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.64 USD

Average target price

11.4 USD

Spread / Average Target

+145.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APPLIED THERAPEUTICS, INC.	+32.69%	530M
VERTEX PHARMACEUTICALS INCORPORATED	+7.47%	111B
REGENERON PHARMACEUTICALS, INC.	+11.23%	106B
BIONTECH SE	-12.50%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.79%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.25%	12.54B
LEGEND BIOTECH CORPORATION	-24.35%	8.09B

Bio Therapeutic Drugs